Non-Hodgkin Lymphoma — Trials

Non-Hodgkin Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

8,120 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 2,168
Recruiting: 1,127
Ph III recruiting: 115
Growth YoY: +5.7%
Industry share: 27%
Top sponsor: National Cancer Institute (NCI)
Termination share: 35.5%
Trials / 1,000 deaths: 108.5 USA 2023 cdc-uscs

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1,290)

clinicaltrialsPublishedShowing 651–700 of 8,120 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07451054	CD45BE-HSPC + CART-45 Cells	recruiting	Phase 1	42	University of PennsylvaniaOTHER	1	Aug 10, 2026	clinicaltrials
NCT07665307	Delayed Toxicities Post-CAR-T	recruiting	—	30	Icahn School of Medicine at Mount SinaiOTHER	1	Aug 10, 2026	clinicaltrials
NCT00461955